Influence of hemodynamic variations on the pharmacokinetics of landiolol in patients undergoing cardiovascular surgery

Naoki Matsumoto, Tohru Aomori, Masafumi Kanamoto, Tadashi Usui, Tatsuya Shiga, Koujirou Yamamoto, Shigeru Saito

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Although landiolol is useful in the emergency management of atrial fibrillation, atrial flutter, and tachycardia, as well as in perioperative arrhythmia control, the influence of hemodynamic changes on the pharmacokinetics of landiolol is unknown. We investigated the influence of hemodynamic variation and the following hepatocirculatory changes after systemic heparinization on the pharmacokinetics of landiolol in patients undergoing cardiovascular surgery under cardiopulmonary bypass. Cardiac output and cardiac index (CI) were continuously monitored in 19 patients using an arterial pressure-based cardiac output monitor. The middle and right hepatic venous blood flow indexes (mHVBFI and rHVBFI) were measured by transesophageal echocardiography, and hemodynamic data were collected at points (T1-T3) as follows: T1, before administration of heparin and after sternotomy; T2, just before systemic heparinization (300 U/kg); T3, 10 min after T2. The plasma concentration of landiolol was measured by HPLC at the same point. After administration of heparin, mean arterial blood pressure, CI, mHVBFI, and rHVBFI were significantly decreased (<0.05). Heart rate was not significantly changed. After systemic heparinization, the landiolol concentration was significantly decreased from 0.407±0. 251&mu;g·mL-1 to 0.232±0. 207&mu;g·mL-1 (<0.01). There was no significant difference between T1 and T2 (=0.88). In conclusion, the plasma concentration of landiolol was decreased by diminished CI due to systemic heparinization, but not affected by the change of hepatic blood flow.

Original languageEnglish
Pages (from-to)1655-1660
Number of pages6
JournalBiological and Pharmaceutical Bulletin
Volume35
Issue number10
DOIs
Publication statusPublished - 2012 Oct
Externally publishedYes

Fingerprint

Pharmacokinetics
Hemodynamics
Arterial Pressure
Cardiac Output
Heparin
Atrial Flutter
Sternotomy
Liver
Transesophageal Echocardiography
Cardiopulmonary Bypass
Tachycardia
Atrial Fibrillation
landiolol
Cardiac Arrhythmias
Emergencies
Heart Rate
High Pressure Liquid Chromatography

Keywords

  • Cardiac index
  • Heparin
  • Hepatic venous blood flow
  • HPLC
  • Landiolol
  • Pseudocholinesterase

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology

Cite this

Influence of hemodynamic variations on the pharmacokinetics of landiolol in patients undergoing cardiovascular surgery. / Matsumoto, Naoki; Aomori, Tohru; Kanamoto, Masafumi; Usui, Tadashi; Shiga, Tatsuya; Yamamoto, Koujirou; Saito, Shigeru.

In: Biological and Pharmaceutical Bulletin, Vol. 35, No. 10, 10.2012, p. 1655-1660.

Research output: Contribution to journalArticle

Matsumoto, Naoki ; Aomori, Tohru ; Kanamoto, Masafumi ; Usui, Tadashi ; Shiga, Tatsuya ; Yamamoto, Koujirou ; Saito, Shigeru. / Influence of hemodynamic variations on the pharmacokinetics of landiolol in patients undergoing cardiovascular surgery. In: Biological and Pharmaceutical Bulletin. 2012 ; Vol. 35, No. 10. pp. 1655-1660.
@article{657208931ad14881a147552bd1529e15,
title = "Influence of hemodynamic variations on the pharmacokinetics of landiolol in patients undergoing cardiovascular surgery",
abstract = "Although landiolol is useful in the emergency management of atrial fibrillation, atrial flutter, and tachycardia, as well as in perioperative arrhythmia control, the influence of hemodynamic changes on the pharmacokinetics of landiolol is unknown. We investigated the influence of hemodynamic variation and the following hepatocirculatory changes after systemic heparinization on the pharmacokinetics of landiolol in patients undergoing cardiovascular surgery under cardiopulmonary bypass. Cardiac output and cardiac index (CI) were continuously monitored in 19 patients using an arterial pressure-based cardiac output monitor. The middle and right hepatic venous blood flow indexes (mHVBFI and rHVBFI) were measured by transesophageal echocardiography, and hemodynamic data were collected at points (T1-T3) as follows: T1, before administration of heparin and after sternotomy; T2, just before systemic heparinization (300 U/kg); T3, 10 min after T2. The plasma concentration of landiolol was measured by HPLC at the same point. After administration of heparin, mean arterial blood pressure, CI, mHVBFI, and rHVBFI were significantly decreased (<0.05). Heart rate was not significantly changed. After systemic heparinization, the landiolol concentration was significantly decreased from 0.407±0. 251&mu;g·mL-1 to 0.232±0. 207&mu;g·mL-1 (<0.01). There was no significant difference between T1 and T2 (=0.88). In conclusion, the plasma concentration of landiolol was decreased by diminished CI due to systemic heparinization, but not affected by the change of hepatic blood flow.",
keywords = "Cardiac index, Heparin, Hepatic venous blood flow, HPLC, Landiolol, Pseudocholinesterase",
author = "Naoki Matsumoto and Tohru Aomori and Masafumi Kanamoto and Tadashi Usui and Tatsuya Shiga and Koujirou Yamamoto and Shigeru Saito",
year = "2012",
month = "10",
doi = "10.1248/bpb.b110727",
language = "English",
volume = "35",
pages = "1655--1660",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "10",

}

TY - JOUR

T1 - Influence of hemodynamic variations on the pharmacokinetics of landiolol in patients undergoing cardiovascular surgery

AU - Matsumoto, Naoki

AU - Aomori, Tohru

AU - Kanamoto, Masafumi

AU - Usui, Tadashi

AU - Shiga, Tatsuya

AU - Yamamoto, Koujirou

AU - Saito, Shigeru

PY - 2012/10

Y1 - 2012/10

N2 - Although landiolol is useful in the emergency management of atrial fibrillation, atrial flutter, and tachycardia, as well as in perioperative arrhythmia control, the influence of hemodynamic changes on the pharmacokinetics of landiolol is unknown. We investigated the influence of hemodynamic variation and the following hepatocirculatory changes after systemic heparinization on the pharmacokinetics of landiolol in patients undergoing cardiovascular surgery under cardiopulmonary bypass. Cardiac output and cardiac index (CI) were continuously monitored in 19 patients using an arterial pressure-based cardiac output monitor. The middle and right hepatic venous blood flow indexes (mHVBFI and rHVBFI) were measured by transesophageal echocardiography, and hemodynamic data were collected at points (T1-T3) as follows: T1, before administration of heparin and after sternotomy; T2, just before systemic heparinization (300 U/kg); T3, 10 min after T2. The plasma concentration of landiolol was measured by HPLC at the same point. After administration of heparin, mean arterial blood pressure, CI, mHVBFI, and rHVBFI were significantly decreased (<0.05). Heart rate was not significantly changed. After systemic heparinization, the landiolol concentration was significantly decreased from 0.407±0. 251&mu;g·mL-1 to 0.232±0. 207&mu;g·mL-1 (<0.01). There was no significant difference between T1 and T2 (=0.88). In conclusion, the plasma concentration of landiolol was decreased by diminished CI due to systemic heparinization, but not affected by the change of hepatic blood flow.

AB - Although landiolol is useful in the emergency management of atrial fibrillation, atrial flutter, and tachycardia, as well as in perioperative arrhythmia control, the influence of hemodynamic changes on the pharmacokinetics of landiolol is unknown. We investigated the influence of hemodynamic variation and the following hepatocirculatory changes after systemic heparinization on the pharmacokinetics of landiolol in patients undergoing cardiovascular surgery under cardiopulmonary bypass. Cardiac output and cardiac index (CI) were continuously monitored in 19 patients using an arterial pressure-based cardiac output monitor. The middle and right hepatic venous blood flow indexes (mHVBFI and rHVBFI) were measured by transesophageal echocardiography, and hemodynamic data were collected at points (T1-T3) as follows: T1, before administration of heparin and after sternotomy; T2, just before systemic heparinization (300 U/kg); T3, 10 min after T2. The plasma concentration of landiolol was measured by HPLC at the same point. After administration of heparin, mean arterial blood pressure, CI, mHVBFI, and rHVBFI were significantly decreased (<0.05). Heart rate was not significantly changed. After systemic heparinization, the landiolol concentration was significantly decreased from 0.407±0. 251&mu;g·mL-1 to 0.232±0. 207&mu;g·mL-1 (<0.01). There was no significant difference between T1 and T2 (=0.88). In conclusion, the plasma concentration of landiolol was decreased by diminished CI due to systemic heparinization, but not affected by the change of hepatic blood flow.

KW - Cardiac index

KW - Heparin

KW - Hepatic venous blood flow

KW - HPLC

KW - Landiolol

KW - Pseudocholinesterase

UR - http://www.scopus.com/inward/record.url?scp=84867279019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867279019&partnerID=8YFLogxK

U2 - 10.1248/bpb.b110727

DO - 10.1248/bpb.b110727

M3 - Article

VL - 35

SP - 1655

EP - 1660

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 10

ER -